Brain cancer is one of the most devastating CNS pathologies. The majority of adult CNS tumors are glial and classified as astrocytic, oligodendrocytic or mixed on the basis of gene expression and morphologic similarities to normal cells of the respective cell type. Gliomas either present as high-grade tumors, or progress towards a higher grade and more un differentiated character as tumor cells acquire additional mutations over time. Patients with lower grade gliomas often survive for many years, but people with infiltrating grade IV astrocytic neoplasm glioblastoma multiforme have a median survival of approximately 1 year. 1 Brain tumor cells display various stem-like characteristics, such as the ability to proliferate indefinitely, form tumors on transplantation and accumulate mutations owing to self-perpetuation, which raises questions of stem-cell involvement in disease etiology. 2 The adult brain, largely composed of highly specialized differentiated cell types, also contains undifferentiated multipotent and self-renewing neural stem cells (NSCs) that could in principle acquire mutations and become transformed. 3, 4 These neural stem/progenitor cells located in areas of adult neurogenesis, such as the hippocampus, subventricular zone and olfactory bulbs, are normally quiescent, but can be induced to proliferate under conditions of stress. 4 In addition, signaling abnormalities frequently found in brain tumors occur in pathways involving/activated by proteins encoded by genes that have been implicated in the regulation of stem-cell proliferation and self-renewal (e.g. EGF [epidermal growth factor], PTEN, Myc, Shh [sonic hedgehog] or Notch). [2] [3] [4] Moreover, brain tumors contain heterogeneous cell populations with regard to the expression of stage-specific differentiation markers, and this heterogeneity has often been compared to the variety of cell types of the NSC lineage observed during normal brain development. 3, 4 The cancer-stem-cell (CSC) model takes these parallels into account and proposes the existence of a multipotent glioma cell of origin characterized by the expression of stem-cell markers, and by the capacity to self-renew and to re-establish a tumor on transplantation. 2 This hypothesis is supported by experiments involving human tumor cells that express the stem-cell marker CD133. 5, 6 When injected into immuno deficient mice, these cells form xenograft tumors that are phenotypically similar to the human tumor. In addition, CD133 + cells exhibit NSC differentiation capabilities in vitro. By contrast, CD133 -cells from the same human tumors are not tumorigenic on transplantation. The CSC model therefore views tumor cells as clonal and differentia ting unidirectionally from the CSC. 2, 5, 6 Potential mechanisms put forth for the derivation of CSCs include aneuploidy, cell fusion and horizontal gene transfer, the proposed cells of origin (the CSCs) being transformed tissue-specific stem cells, bone-marrow stem cells, or somatic cells that have undergone transdifferentiation. 7 The practical implication of the CSC model is that CSCs are resistant to radiation and chemotherapy, and are proposed to account for tumor recurrence. 2 Brain tumorigenesis, however, is probably more complex than the clonal CSC model suggests. In addition to a variety of cells expressing markers of the neural lineage, primary brain tumors contain cells of other developmental stages and lineages on the basis of their morphology and gene expression. Some cells within a tumor do not arise from the cell(s) of origin, but rather represent normal cells trapped in the tumor as it infiltrates normal brain structures. In addition, normal NSCs are extensively tumor-tropic in in vivo intracranial xenograft glioma models and home to tumor cells, implying that normal stem cells contribute to the tumor mass. 8 Therefore, brain tumors contain both the progeny of the tumor cell(s) of origin and recruited progenitor cells from adjacent brain and possibly other sites. 8, 9 These normal cells could subsequently become transformed.
Many studies supporting the hypothesis of CSCs as tumor cells of origin assess differential 
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tumorigenicity of various cells within a tumor on the basis of cell-surface marker expression, and extend characteristics of normal stem cells to CSCs. Tumor cells, however, aberrantly express a variety of genes, and are therefore difficult to categorize as a particular cell type in normal development. A brain tumor cell's ability to express stem-cell markers or to give rise to different cell types of the neural lineage in vitro does not make it a true stem cell. It is possible that some cells that fit the criteria for CSCs are in fact derived from transformed recruited cells, making the presence of some stem cells within the tumor a consequence rather than a cause of brain tumorigenesis. 2, 9 Mouse modeling experiments unravel additional complexity with regard to the involvement of stem or progenitor cells in gliomagenesis. Combined activation of ras and akt initiates gliomas from nestin-positive progenitor cells, but not from differentiated astrocytes expressing glial fibrillary acidic protein (GFAP). 9 The latter cell type can be sensitized to oncogenic stimuli by overexpression of the oncogene Myc or by loss of the tumor suppressor locus Ink4a/Arf, both of which induce undifferentiated character in vitro. 9 These findings show that differentiated cells can give rise to highly undifferentiated tumors depending on a combination of mutations, indicating that the apparent differentiation state of brain tumor cells depends on signaling abnormalities causally related to tumorigenesis. Changes in signaling also alter apparent lineage of brain tumor cells: forced Akt activation shifts platelet-derived growth factor (PDGF)-stimulated oligodendroglioma cells towards astrocytic morphology, whereas treatment with mTOR (mammalian target of rapamycin) inhibitors converts astrocytic tumor cells to oligodendroglial morphology in vitro and in vivo. 9 Documentation of paracrine effects in modeled brain tumors corroborates the recruitment hypothesis. PDGFβ, which maintains glial precursors undifferentiated in culture, is sufficient for tumor formation in both nestin-positive and GFAP-positive cells, and has dose-dependent effects on tumor incidence, high-grade character, and recruitment of vascular smooth muscle cells for tumor angiogenesis. 10 Therefore, tumor heterogeneity could be a result of an inherent regional instability in the gene expression and signaling patterns that regulate the apparent lineage and differentiation state. Genetic alterations make the differentia tion status of brain tumor cells unstable and dynamic to the extent that it becomes impossible to assign a differentiation state at all. The existence of NSCs and other tumor cell popula tions not derived from the cell(s) of origin but potentially recruited from the brain, bone marrow or other sources further complicates the picture. [8] [9] [10] Defining events during tumorigenesis is key to understanding the highly dynamic and complex nature of brain tumor biology and etiology. Current brain tumor treatments (surgery, chemotherapy and radiation therapy) remove tumor bulk and target rapidly prolifera ting cells but are unable to eradicate the full scope of cancer cell heterogeneity, indicating the need for novel combination therapies. Residual and perhaps quiescent brain tumor stem-like cells, regardless of their origin, might allow cancer to recur, evolving into a more aggressive and malignant form. 2, 9 Hence, we need an improved understanding of stem-cell character in brain tumorigenesis and of normal stem-cell biology as it applies to the molecular regulation of cell differentiation in time and space. If brain tumors are composed of both progeny of tumor cell(s) of origin and recruited cells, and if stem-like character exists in both populations, understanding tumor initiation and targeting the originating cancer cells might eliminate autocrine and paracrine effects that drive tumorigenesis. [8] [9] [10] 
